CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (661)	5/17/2002 11:13:02 PM
From: Mike McFarland	Read Replies (1) of 675

CeNeS announces further progress in its Neuropathic Pain Phase II Programme cenes.com It was strange--in the space of two days I got an email about the ggf2/schizophrenia thing and the one listed above. (the ggf email pointed out that CeNeS is the sole owner, strange they would send an email out for that out of the blue. Anyway, fwiw, it is also called Neuregulin-1) Anyway, I have not kept up with CeNeS too much, last October I printed out this glowing report about how CeNeS was going to turn things around and such, but the shares just kept sagging. I hope there is still something here worth owning. I've not given up any of my shares. Even when you have been stopped out of the market as I have (at least for trading) it is hardly worth it to dump your penny stocks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next